DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Abstract
Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma (DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms through which it occurs are incompletely understood [1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still evolve into aggressive forms resistant even to newer therapies [2].
Description
Keywords
DDX3X mutation, Drug resistance, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Antineoplastic Agents, Biomarkers, Tumor, Cell Line, Tumor, Cyclin D1, DEAD-box RNA Helicases, Disease Progression, Drug Resistance, Neoplasm, Humans, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Mitogen-Activated Protein Kinases, Mutation, Prognosis, STAT3 Transcription Factor, Exome Sequencing
Journal Title
Mol Cancer
Conference Name
Journal ISSN
1476-4598
1476-4598
1476-4598
Volume Title
20
Publisher
Springer Science and Business Media LLC
Publisher DOI
Sponsorship
Wellcome Trust (203151/Z/16/Z)
Medical Research Council (MR/M008584/1)
Cancer Research UK (A25117)
Medical Research Council (MR/M008584/1)
Cancer Research UK (A25117)
This research was supported, in part, by Start-Up Grant to NKV provided
by Lee Kong Chian School of Medicine, Nanyang Technological University
Singapore (L0412290), the Singapore Ministry of Education (MOE) under its
MOE Academic Research Fund (AcRF) Tier 2 Grant (MOE2017-T2–2-004), and
the National Research Foundation Singapore under its Open Fund Large
Collaborative Grant (OFLCG18May-0028) and administered by the Singapore
Ministry of Health’s National Medical Research Council (NMRC). N.F.G.
acknowledges funding support from the Singapore Ministry of Health’s
National Medical Research Council under its NMRC of Singapore Transition
Award (NMRC/TA/0051/2016), Kay Kendall Leukaemia Fund Junior Clinical
Research Training Fellowship (KKL649) and the Addenbrooke’s Charitable
Trust Research Training Fellowship. D.H. was supported by the Medical
Research Council (MR/M008584/1) and Blood Cancer UK and receives core
funding from Wellcome (203151/Z/16/Z) and MRC to the Wellcome-MRC
Cambridge Stem Cell Institute and from the CRUK Cambridge Centre
(A25117). A.K. and Z.S.P. were provided with PhD fellowship by Lee Kong
Chian School of Medicine, Nanyang Technological University Singapore.
B.H.S.W. was provided with PhD fellowship by HealthTech NTU, Nanyang
Technological University Singapore.